CLINICAL DEVELOPMENT STRATEGY & PIVOTAL TRIAL DESIGN

Design that is credible before it becomes expensive

Regulator- and payer-credible development architecture built around the decisions the program must support.

The problem

A protocol can be executable and still answer the wrong question

Population, endpoints, estimands, comparator, duration, sample size and feasibility are often optimized separately. The study may run, yet the result can remain difficult to interpret, defend, reimburse or finance.

What we do

Build one evidence architecture

Clinical development plan and target product profile
Indication, population and development-thesis challenge
Pivotal design options and decision logic
Endpoint, estimand, comparator and sample-size review
Feasibility and protocol-burden stress test
Regulatory, HTA and payer evidence alignment
Risk map, mitigation plan and decision gates

Best fit

Use this mandate before design choices harden

Before a Phase II or pivotal protocol is finalized
Before scientific advice or an end-of-Phase meeting
When a development thesis must be rebuilt around new data
When payer and operational requirements have entered too late
When an investor or board needs independent design scrutiny

WHAT CHANGES AFTER THE ENGAGEMENT

From a plausible protocol to a decision-grade pivotal architecture

Representative anonymised example from a rare-disease / complex-CNS pivotal program. The objective was not to add more strategy slides, but to remove the design choices most likely to weaken regulatory interpretation, payer credibility and operational signal protection.

BEFORE

Interpretability risk was locked into design choices

Endpoint and estimand choices, payer evidence needs and operational noise controls were not yet integrated into one pivotal logic.

INTERVENTION

One architecture replaced parallel functional plans

Endpoint and estimand strategy were aligned with FDA/EMA and HTA/HEOR logic, with guardrails for baseline control, rater strategy and reading approach.

WHAT CHANGED

The protocol became submission- and payer-credible

The engagement produced a submission-ready protocol package, a stronger payer evidence narrative and clearer differentiation logic for future launch and partnering decisions.

VALUE PROTECTED

Reduced risk of a positive but strategically weak trial

Regulatory, payer, commercial and operational logic were integrated before protocol lock, protecting future interpretability and decision value.

View more verified case snapshots →

Carry the design into execution

A decision-grade next step

Design the evidence before assumptions become expensive.

Pressure-test the study against regulatory, payer, investor and execution reality.